Prelude Therapeutics Incorporated PRLD
3.79 USD -0.05 (-1.31%)
Nov 3, 2026, 3:39 PM EST
3.76 Day range 4.00
1.17 52-week range 6.83
- YTD
- +30.68%
- 1 year
- -4.78%
Financial health
Altman Z-Score
-3.03 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 2
Valuation
P/E -2.2×
FY 2018 5y median -2.2× FY 2025
P/S 18.4×
FY 2018 5y median 0.0× FY 2025
P/B 3.3×
FY 2018 5y median 1.5× FY 2025
P/FCF -4.0×
FY 2018 5y median -3.3× FY 2025
EV/EBITDA -1.5×
FY 2018 5y median -1.5× FY 2025
EV/Sales 11.9×
FY 2018 5y median 0.0× FY 2025
FCF Yield -25.3%
FY 2018 5y median -30.3% FY 2025
Profitability
Gross Margin 85.9%
FY 2018 5y median 0.0% FY 2025
Operating Margin -861.3%
FY 2018 5y median 0.0% FY 2025
Net Margin -819.6%
FY 2018 5y median 0.0% FY 2025
ROE -145.0%
FY 2018 5y median -59.1% FY 2025
ROIC -114.8%
FY 2018 5y median -61.6% FY 2025
ROA -70.4%
FY 2018 5y median -52.4% FY 2025
Growth (YoY)
Revenue 73.4%
FY 2018 FY 2025
Operating Income 25.2%
FY 2018 FY 2025
EPS (diluted) 23.2%
FY 2018 FY 2025
Free Cash Flow 45.6%
FY 2018 FY 2025
Financial Health
Current Ratio 2.0×
FY 2018 5y median 9.4× FY 2025
Quick Ratio 2.0×
FY 2018 5y median 9.4× FY 2025
Debt / Equity 0.3×
FY 2018 5y median 0.1× FY 2025
Net Debt / EBITDA 0.2×
FY 2018 5y median 0.2× FY 2025
Interest Coverage 0.0×
FY 2018 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2018 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2018 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31